MAIN CONTENT
Healthcare stocks lead the rebound
The STOXX 600 rose about 0.8% on the morning of October 6, putting the benchmark on course for a third consecutive gain. Healthcare led sectoral performance with a rise of roughly 1.4%, showing how a powerful corporate catalyst can temporarily overshadow Europe’s macroeconomic anxieties. Genmab jumped 7.7% to a three-year high and became the clearest single-stock story of the session.
The catalyst was EPCORE DLBCL-2, a Phase 3 trial of epcoritamab plus R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma. Genmab and AbbVie said the combination delivered a statistically significant and clinically meaningful improvement in progression-free survival and reduced the risk of disease progression or death by 51% versus R-CHOP alone. For investors, the result represents both medical progress and a stronger commercial case for a bispecific antibody in frontline treatment.
Bond markets calm, but the rate burden remains
Euro-area government bond yields retreated after touching multi-decade highs in the previous week. The spread between French and German 10-year yields also narrowed, suggesting that some investors believed France’s risk premium had risen too far, too quickly.

















